Last update and review: December 1st, 2020.
Ian Lipkin, “Professor, Director, Center for Infection and Immunity”, at Columbia University, New York, got infected with SARS-CoV-2 and progressed to a symptomatic COVID-19.
Ian Lipkin is a frequent guest of different media and podcasts. He told the story of how his disease was progressing on a podcast published on March 28, 2020, while Lipkin was still symptomatic.
Ian Lipkin considered using blood plasma from Chinese patients who recovered from COVID-19 that his beloved friends, Chinese scientists, wanted to send him from China, but later decided against using it. Someone smart apparently advised Ian Lipkin against using plasma from recovered Chinese patients.
Ian Lipkin started Hydroxychloroquine but used a wrong dosage and protocol. As Ian Lipkin explained it: “I did not feel well after that initial dose of 800mg… I had an episode of diarrhea soon after I took it.”
The New Neander’s Medical on September 27, 2020:
Chloroquine (and possibly hydroxychloroquine) potently inhibits the diamine oxidase (DAO) enzyme in vitro (greater than 90%). DAO is involved in deactivating histamine.
Diarrhea is associated with histamine intolerance/poisoning. Chloroquine potently inhibits DAO, an enzyme involved in the deactivation of the dietary histamine. We see diarrhea as one of the adverse effects in patients treated with hydroxychloroquine.
Apparently, Ian Lipkin, “Professor, Director, Center for Infection and Immunity”, and the physicians who treated him, did not bother to look up the dosages and protocols used in existing trials of hydroxychloroquine in COVID-19 patients. Lipkin most likely used the dosage for treating malaria. Indeed, the drug label information for hydroxychloroquine approved by the FDA for the US mentions 800mg as an initial dose in treating uncomplicated malaria.
Treatment of Uncomplicated Malaria
Adults: 800 mg (620 mg base) followed by 400 mg (310 mg base) at 6 hours, 24 hours and 48 hours after the initial dose (total 2000 mg hydroxychloroquine sulfate or 1550 mg base).
Ian Lipkin later said that he was not sure if hydroxychloroquine was of any help in his case. Lipkin also said that he did not use azithromycin, a macrolide antibiotic used in combination with hydroxychloroquine in some of the recent trials.
Analysis.
The recent successful trials of hydroxychloroquine for treating COVID-19 did not use a high first dose. Initial loading with hydroxychloroquine is questionable in the treatment of COVID-19.
The wrong dosage of hydroxychloroquine and the wrong protocol used by Ian Lipkin is an embarrassing episode that shows a low professional level of New York professors of medicine and medical doctors.
An update from December 1, 2020.
By December 2020, it became clear that the “medical profession” failed to discover the right protocols for using hydroxychloroquine. There were a lot of trials in different countries. But most of them used wrong protocols and yield inconclusive results.
The thesis about a low professional level of medical doctors in New York was also confirmed:
2 Comments